Interesse Geral
Dr. Fauci afirma que os riscos trazidos pela variante Delta acentuam a importância das vacinas.
18 Jun, 2021 | 10:38hDr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR
Opinião | Causalidade ou confusão: por que os grupos controle são fundamentais para caracterizar a “long COVID” – “Muitos dos sintomas autorrelatados, como cefaleias intermitentes ou cansaço, são inespecíficos e prevalentes na população geral.”
18 Jun, 2021 | 10:37hCausation or confounding: why controls are critical for characterizing long COVID – Nature
Estudo mostra que a taxa de reinfecção por COVID-19 é inferior a 1% em pacientes que tiveram doença grave.
18 Jun, 2021 | 10:35hEstudo original: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases
OMS | Taxas de partos cesarianos continuam a subir, em meio ao aumento nas desigualdades de acesso.
18 Jun, 2021 | 10:32hEstudo original: Trends and projections of caesarean section rates: global and regional estimates – BMJ Global Health
Comentário no Twitter (fio – clique para saber mais)
Caesarean section use continues to rise 📈 globally, now accounting for more than 1 in 5 of all childbirths.
C-section can put women and babies at unnecessary risk of short- and long-term health problems if performed when there is not medical need
— World Health Organization (WHO) (@WHO) June 17, 2021
Agora, o CDC chama a variante Delta do coronavírus de “variante de preocupação”.
17 Jun, 2021 | 11:02hCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Diretriz: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Comentário no Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
As designações de autoria nos artigos que podem prejudicar as colaborações científicas.
17 Jun, 2021 | 10:52hThe authorship rows that sour scientific collaborations – Nature
De acordo com um novo relatório, quase 25% dos pacientes que tiveram COVID-19 desenvolvem sintomas de longa duração.
16 Jun, 2021 | 10:55hAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Relatório original: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Comentário no Twitter (fio – clique para saber mais)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Perspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”
16 Jun, 2021 | 10:52hA long-term perspective on immunity to COVID – Nature
[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
Variante Delta do SARS-CoV-2 na Escócia: demografia, risco de admissão hospitalar e eficácia das vacinas – “O risco de admissão hospitalar por COVID-19 foi aproximadamente o dobro nos contaminados pela variante Delta em comparação aos contaminados pela variante Alfa.”
15 Jun, 2021 | 11:34hComentários: Delta may raise hospitalisation but vaccine still protects – UK Research and Innovation E Expert reaction to Lancet research letter analysing data from Scotland on the Delta variant, looking at demographics, risk of hospital admission and vaccine effectiveness – Science Media Centre
Comentário no Twitter (fio – clique para saber mais)
Just published @TheLancet
The #DeltaVariant experience in Scotlandhttps://t.co/IfjDJnCAMC
1. #VaccinesWork ("AZ appeared less effective than Pfizer")
2. Younger, unvaccinated got the delta infections
3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant pic.twitter.com/cP8clu57Rd— Eric Topol (@EricTopol) June 14, 2021